CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 238

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage 3b/c or Stage 4 Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222893

Enrollment

800

Registered

2015-06-19

Start date

2015-08-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Interventions

investigational material(s) Generic name etc : Ipilimumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects less than 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is at least 18 years of age. Completely removed melanoma by surgery performed within 12 weeks of randomization. Stage 3b/C or Stage 4 before complete resection. No previous anti-cancer treatment.

Exclusion criteria

Exclusion criteria: Ocular or uveal melanoma. History of carcinomatosis meningitis. History of auto-immune disease. Treatment directed against the resected melanoma that is administrated after the surgery.

Design outcomes

Primary

Measure	Time frame
Recurrence -free-survival.	—

Secondary

Measure	Time frame
Overall survival.	—

Countries

Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026